Merck KGaA

Merck KGaA and Promega Collaborate on Drug Screening Technologies

Merck's Precem-TcT drug shows positive results in Phase I clinical trial

Merck KgaA Signs Agreement with US Government to Expand IVF Access

Merck and Opentrons Collaborate to Launch AAW Automated Detection Workstation

Merck's enpatoran Phase II Study B Group Shows Positive Results for SLE Treatment

Merck's Pimicotinib Obtains Marketing Approval in China

First Eagle Invests in Merck, Holding 5.12% Stake

Merck Announces Positive Phase III Trial Results for Pimicotinib in Treating Tenosynovial Giant Cell Tumor

Merck and imec Collaborate on Microphysiological System Platform

CFO of Merck in Germany Indicates Readiness to Deal with Tariffs

Germany's Merck KGaA reported higher Q3 earnings and sales, driven by demand for semiconductor materials and pharma tools, boosting shares by up to 8.6%. The life-science segment saw recovery from post-pandemic slumps, while AI demand lifted semiconductor sales. Merck's after-tax profit was €898M, with EBITDA up 3.1% to €1.67B. Net sales grew 5.2% to €5.32B. Merck narrowed its full-year outlook, expecting 3% organic sales growth and 5%-7% EBITDA growth.

marketscreener

Germany's Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results -- Update

UBS analyst Matthew Weston has reaffirmed a Buy rating on Merck KGaA, setting a price target of €150.00. Weston, who specializes in the Healthcare sector, has an average return of 7.1% and a 69.77% success rate on his stock recommendations. Additionally, J.P. Morgan's Richard Vosser also issued a Buy rating for Merck KGaA today, while Stifel Nicolaus maintained a Sell rating on the stock.

Tip Ranks

UBS Remains a Buy on Merck KGaA (0O14)

Germany's Merck KGaA reported a 5.2% organic growth in net sales, reaching EUR 5.32 billion for Q3, with an after-tax profit of EUR 898 million. The company's EBITDA before exceptional items rose to EUR 1.67 billion, exceeding analyst expectations. Merck has narrowed its 2025 outlook, projecting organic sales growth of around 3% and EBITDA growth of 5%-7%. The guidance midpoints remain unchanged, with expected sales between EUR 20.8 billion and EUR 21.4 billion for 2025.

Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units

Merck KGaA Logs Higher Q3 Attributable Profit, Net Sales

Merck KGaA Logs Higher Q3 Attributable Profit, Net Sales

Merck KGaA's Q3 profit rises, beats market view

Merck KGaA's Q3 profit rises, beats market view

According to TipRanks, Vosser is a 3-star analyst with an average return of 2.4% and a 49.28% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Sanofi. Merck KGaA has an analyst consensus of Moderate Buy, with a price target consensus of €145.38, a 28.14% upside from current levels. In a report released on October 29, UBS also maintained a Buy rating on the stock with a €150.00 price target.

Merck KGaA (0O14) Gets a Buy from J.P. Morgan

Merck KGaA has partnered with Promega Corporation to co-develop technologies for drug screening and discovery. This collaboration aims to enhance access to 3D cell models relevant to diseases by combining MilliporeSigma’s expertise in chemistry and organoids with Promega’s advanced assay technologies. The partnership will also explore new workflows for studying protein interactions, reinforcing Merck KGaA’s position in next-generation biology and drug discovery solutions.

Reuters

Merck KGaA Partners with Promega to Advance 3D Cell Drug Discovery Technologies

Merck KGaA (OTCMKTS:MKKGY) shares rose 0.3% to $26.85, with trading volume increasing by 115% compared to the average. Analysts have mixed ratings, with Zacks upgrading to 'hold' and Barclays downgrading from 'strong-buy' to 'hold'. The company reported Q2 earnings of $0.57 per share, exceeding estimates, and revenue of $6.11 billion. Merck KGaA has a market cap of $17.35 billion and a PE ratio of 11.28. Analysts predict an EPS of 1.87 for the current fiscal year.

Market Beat

Merck KGaA (OTCMKTS:MKKGY) Trading 0.3% Higher   - Here's What Happened

According to TipRanks, Friedrichs is an analyst with an average return of -2.8% and a 40.72% success rate. Friedrichs covers the Healthcare sector, focusing on stocks such as Merck KGaA, Gerresheimer, and SCHOTT Pharma AG & Co. KGaA. In addition to Deutsche Bank , Merck KGaA also received a Buy from DZ BANK AG’s Peter Spengler in a report issued yesterday. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Merck KGaA (LSE: 0O14).

Deutsche Bank  Keeps Their Buy Rating on Merck KGaA (0O14)

Merck KGaA's antibody-drug conjugate (ADC), Precem-TcT, has advanced to Phase III trials for colorectal cancer after positive results from the Phase I PROCEADE-CRC-01 study, which showed a 31% objective response rate and a median progression-free survival of 6.9 months. The drug demonstrated safety with manageable adverse events. The competition in the ADC market is intense, with Merck aiming to combine Precem-TcT with existing therapies for better efficacy. Phase III trials are expected to start in early 2026.

Pharmaceutical Technology

ESMO 2025: Merck KGaA’s ADC leapfrogs to Phase III in colorectal cancer

Merck KGaA's subsidiary, SpringWorks Therapeutics, published long-term efficacy and safety data from a Phase 3 trial of Ogsiveo for treating desmoid tumors in the Journal of Clinical Oncology. The study showed that treatment for up to four years led to a tumor size reduction and an increase in the objective response rate (ORR), which reached 45.7% after four years. The trial involved 142 patients and received orphan drug designation from US and European health authorities.

Merck KGaA presents encouraging data in desmoid tumors

Merck KGaA has reported positive long-term results from the Phase 3 program for pimicotinib, a treatment for giant cell tumors of tendon sheaths. The objective response rate improved to 76.2% with a median follow-up of 14.3 months, showing enhancements in pain, stiffness, and physical function. No new safety concerns were noted. Victoria Zazulina emphasized the drug's potential to improve tumor reduction and quality of life. A marketing authorization application is under review in China, with plans for submissions in the U.S. and other regions.

Merck KGaA presents positive long-term results for pimicotinib

Merck KGaA's application for marketing authorization of pimicotinib, a CSF-1R inhibitor for treating tenosynovial giant cell tumor (TGCT), has been accepted for review by China's NMPA. The company plans to submit additional regulatory applications in the U.S. and other markets. No multi-organization funding was mentioned in the announcement.